{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:28:16Z","timestamp":1793104096658,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"publisher","award":["229154"],"award-info":[{"award-number":["229154"]}],"id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"publisher","award":["233040"],"award-info":[{"award-number":["233040"]}],"id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02650-3","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:02:10Z","timestamp":1776038530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth"],"prefix":"10.1038","volume":"11","author":[{"given":"Tomohiro","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DuoYao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tokudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derick","family":"Okwan-Duodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren G.","family":"Tourtellotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2650_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2650_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely, M. D., Zhang, T. & Chen, L. Resistance mechanisms to Anti-PD cancer immunotherapy. Annu Rev. Immunol. 40, 45\u201374 (2022).","journal-title":"Annu Rev. Immunol."},{"key":"2650_CR3","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","volume":"10","author":"R Bai","year":"2020","unstructured":"Bai, R. et al. Mechanisms of cancer resistance to immunotherapy. Front. Oncol. 10, 1290 (2020).","journal-title":"Front. Oncol."},{"key":"2650_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"2650_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200\u2013218 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2650_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74\u201395 (2017).","journal-title":"Cell Res."},{"key":"2650_CR7","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.4049\/jimmunol.1500325","volume":"195","author":"I Mattiola","year":"2015","unstructured":"Mattiola, I. et al. Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1\u03b2, IFN-\u03b2, and IL-15 pathways. J. Immunol. 195, 2818\u20132828 (2015).","journal-title":"J. Immunol."},{"key":"2650_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14\u201320 (2014).","journal-title":"Immunity"},{"key":"2650_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958\u2013969 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"2650_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723\u2013737 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"2650_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-022-02272-x","volume":"41","author":"N Kumari","year":"2022","unstructured":"Kumari, N. & Choi, S. H. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J. Exp. Clin. Cancer Res. 41, 68 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2650_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2650_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s11658-020-00225-w","volume":"25","author":"DY Cao","year":"2020","unstructured":"Cao, D. Y. et al. Role of angiotensin-converting enzyme in myeloid cell immune responses. Cell Mol. Biol. Lett. 25, 31 (2020).","journal-title":"Cell Mol. Biol. Lett."},{"key":"2650_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2018.15","volume":"14","author":"KE Bernstein","year":"2018","unstructured":"Bernstein, K. E. et al. Angiotensin-converting enzyme in innate and adaptive immunity. Nat. Rev. Nephrol. 14, 325\u2013336 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"2650_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107388","volume":"300","author":"KE Bernstein","year":"2024","unstructured":"Bernstein, K. E. et al. Classical and nonclassical effects of angiotensin-converting enzyme: How increased ACE enhances myeloid immune function. J. Biol. Chem. 300, 107388 (2024).","journal-title":"J. Biol. Chem."},{"key":"2650_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2016-11-752006","volume":"130","author":"Z Khan","year":"2017","unstructured":"Khan, Z. et al. Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils. Blood 130, 328\u2013339 (2017).","journal-title":"Blood"},{"key":"2650_CR17","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1074\/jbc.RA118.006275","volume":"294","author":"Z Khan","year":"2019","unstructured":"Khan, Z. et al. Overexpression of the C-domain of angiotensin-converting enzyme reduces melanoma growth by stimulating M1 macrophage polarization. J. Biol. Chem. 294, 4368\u20134380 (2019).","journal-title":"J. Biol. Chem."},{"key":"2650_CR18","doi-asserted-by":"publisher","first-page":"eabj2138","DOI":"10.1126\/scitranslmed.abj2138","volume":"13","author":"DY Cao","year":"2021","unstructured":"Cao, D. Y. et al. An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo. Sci. Transl. Med. 13, eabj2138 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2650_CR19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/cvr\/cvad082","volume":"119","author":"D Cao","year":"2023","unstructured":"Cao, D. et al. Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor alpha and fundamentally changing lipid metabolism. Cardiovasc Res 119, 1825\u20131841 (2023).","journal-title":"Cardiovasc Res"},{"key":"2650_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","volume":"5","author":"N Wang","year":"2014","unstructured":"Wang, N., Liang, H. & Zen, K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 5, 614 (2014).","journal-title":"Front Immunol."},{"key":"2650_CR21","first-page":"e4181","volume":"8","author":"DN Vatakis","year":"2012","unstructured":"Vatakis, D. N. et al. Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J. Vis. Exp. 8, e4181 (2012).","journal-title":"J. Vis. Exp."},{"key":"2650_CR22","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1089\/scd.2016.0193","volume":"25","author":"DJ Smith","year":"2016","unstructured":"Smith, D. J. et al. Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. Stem Cells Dev. 25, 1863\u20131873 (2016).","journal-title":"Stem Cells Dev."},{"key":"2650_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231\u2013238 (2011).","journal-title":"Nat. Immunol."},{"key":"2650_CR24","doi-asserted-by":"publisher","first-page":"245804","DOI":"10.1155\/2013\/245804","volume":"2013","author":"M Weiss","year":"2013","unstructured":"Weiss, M., Blazek, K., Byrne, A. J., Perocheau, D. P. & Udalova, I. A. IRF5 is a specific marker of inflammatory macrophages in vivo. Mediat. Inflamm. 2013, 245804 (2013).","journal-title":"Mediat. Inflamm."},{"key":"2650_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1084\/jem.20151764","volume":"213","author":"D Langlais","year":"2016","unstructured":"Langlais, D., Barreiro, L. B. & Gros, P. The macrophage IRF8\/IRF1 regulome is required for protection against infections and is associated with chronic inflammation. J. Exp. Med. 213, 585\u2013603 (2016).","journal-title":"J. Exp. Med."},{"key":"2650_CR26","doi-asserted-by":"publisher","first-page":"731023","DOI":"10.1155\/2013\/731023","volume":"2013","author":"R G\u00fcnthner","year":"2013","unstructured":"G\u00fcnthner, R. & Anders, H. J. Interferon-regulatory factors determine macrophage phenotype polarization. Mediat. Inflamm. 2013, 731023 (2013).","journal-title":"Mediat. Inflamm."},{"key":"2650_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","volume":"57","author":"T Kawai","year":"2024","unstructured":"Kawai, T., Ikegawa, M., Ori, D. & Akira, S. Decoding Toll-like receptors: recent insights and perspectives in innate immunity. Immunity 57, 649\u2013673 (2024).","journal-title":"Immunity"},{"key":"2650_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41423-025-01257-y","volume":"22","author":"S Saito","year":"2025","unstructured":"Saito, S. et al. Peroxisome proliferator-activated receptor alpha is an essential factor in enhanced macrophage immune function induced by angiotensin-converting enzyme. Cell Mol. Immunol. 22, 243\u2013259 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"2650_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko, J. H. & Hollmen, M. Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br. J. Cancer 131, 627\u2013640 (2024).","journal-title":"Br. J. Cancer"},{"key":"2650_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. npj. Precis. Oncol. 8, 31 (2024).","journal-title":"npj. Precis. Oncol."},{"key":"2650_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.112.006809","volume":"65","author":"KE Bernstein","year":"2013","unstructured":"Bernstein, K. E. et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharm. Rev. 65, 1\u201346 (2013).","journal-title":"Pharm. Rev."},{"key":"2650_CR32","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s43587-025-00879-1","volume":"5","author":"AR Gomez","year":"2025","unstructured":"Gomez, A. R. et al. Boosting angiotensin-converting enzyme (ACE) in microglia protects against Alzheimer\u2019s disease in 5xFAD mice. Nat. Aging 5, 1280\u20131294 (2025).","journal-title":"Nat. Aging"},{"key":"2650_CR33","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.2353\/ajpath.2007.061205","volume":"170","author":"XZ Shen","year":"2007","unstructured":"Shen, X. Z. et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am. J. Pathol. 170, 2122\u20132134 (2007).","journal-title":"Am. J. Pathol."},{"key":"2650_CR34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1172\/JCI31422","volume":"117","author":"A Sica","year":"2007","unstructured":"Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Investig. 117, 1155\u20131166 (2007).","journal-title":"J. Clin. Investig."},{"key":"2650_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","volume":"31","author":"SJ Van Dyken","year":"2013","unstructured":"Van Dyken, S. J. & Locksley, R. M. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31, 317\u2013343 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"2650_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang, N. & Bevan, M. J. CD8(+) T cells: foot soldiers of the immune system. Immunity 35, 161\u2013168 (2011).","journal-title":"Immunity"},{"key":"2650_CR37","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fphar.2018.00642","volume":"9","author":"Y Tai","year":"2018","unstructured":"Tai, Y., Wang, Q., Korner, H., Zhang, L. & Wei, W. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front. Pharm. 9, 642 (2018).","journal-title":"Front. Pharm."},{"key":"2650_CR38","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/cancers14143546","volume":"14","author":"A Vermare","year":"2022","unstructured":"Vermare, A., Gu\u201arin, M. V., Peranzoni, E. & Bercovici, N. Dynamic CD8(+) T cell cooperation with macrophages and monocytes for successful cancer immunotherapy. Cancers 14, 3456 (2022).","journal-title":"Cancers"},{"key":"2650_CR39","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/ni.2107","volume":"12","author":"XZ Shen","year":"2011","unstructured":"Shen, X. Z. et al. The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat. Immunol. 12, 1078\u20131085 (2011).","journal-title":"Nat. Immunol."},{"key":"2650_CR40","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/labinvest.2017.32","volume":"97","author":"T Zhao","year":"2017","unstructured":"Zhao, T., Bernstein, K. E., Fang, J. & Shen, X. Z. Angiotensin-converting enzyme affects the presentation of MHC class II antigens. Lab Investig. 97, 764\u2013771 (2017).","journal-title":"Lab Investig."},{"key":"2650_CR41","doi-asserted-by":"publisher","first-page":"21659","DOI":"10.1073\/pnas.1007654108","volume":"107","author":"F Bellora","year":"2010","unstructured":"Bellora, F. et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc. Natl. Acad. Sci. USA 107, 21659\u201321664 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2650_CR42","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/blood-2006-10-052977","volume":"109","author":"S Nedvetzki","year":"2007","unstructured":"Nedvetzki, S. et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 109, 3776\u20133785 (2007).","journal-title":"Blood"},{"key":"2650_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1189\/jlb.0311171","volume":"90","author":"N Romo","year":"2011","unstructured":"Romo, N. et al. Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J. Leukoc. Biol. 90, 717\u2013726 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"2650_CR44","first-page":"403","volume":"3","author":"T Michel","year":"2012","unstructured":"Michel, T., Hentges, F. & Zimmer, J. Consequences of the crosstalk between monocytes\/macrophages and natural killer cells. Front. Immunol. 3, 403 (2012).","journal-title":"Front. Immunol."},{"key":"2650_CR45","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","volume":"4","author":"R Sakemura","year":"2016","unstructured":"Sakemura, R. et al. A tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol. Res 4, 658\u2013668 (2016).","journal-title":"Cancer Immunol. Res"},{"key":"2650_CR46","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3389\/fimmu.2020.02044","volume":"11","author":"M Tristan-Manzano","year":"2020","unstructured":"Tristan-Manzano, M. et al. Externally-controlled systems for immunotherapy: from bench to bedside. Front Immunol. 11, 2044 (2020).","journal-title":"Front Immunol."},{"key":"2650_CR47","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.3390\/cancers14215273","volume":"14","author":"T Shibata","year":"2022","unstructured":"Shibata, T. et al. miR766-3p and miR124-3p dictate drug resistance and clinical outcome in HNSCC. Cancers 14, 5273 (2022).","journal-title":"Cancers"},{"key":"2650_CR48","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.stemcr.2015.01.005","volume":"4","author":"N Lachmann","year":"2015","unstructured":"Lachmann, N. et al. Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Rep. 4, 282\u2013296 (2015).","journal-title":"Stem Cell Rep."},{"key":"2650_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/sctm.18-0255","volume":"8","author":"LR Trump","year":"2019","unstructured":"Trump, L. R. et al. Neutrophils derived from genetically modified human induced pluripotent stem cells circulate and phagocytose bacteria in vivo. Stem Cells Transl. Med. 8, 557\u2013567 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"2650_CR50","first-page":"467","volume":"55","author":"IM Redelsperger","year":"2016","unstructured":"Redelsperger, I. M. et al. Stability of doxycycline in feed and water and minimal effective doses in tetracycline-inducible systems. J. Am. Assoc. Lab Anim. Sci. 55, 467\u2013474 (2016).","journal-title":"J. Am. Assoc. Lab Anim. Sci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02650-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:50:23Z","timestamp":1791863423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02650-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2650"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02650-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the Acknowledgements section was updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A provisional patent application (Number: 63\/948,964) for these findings has been submitted. The authors declare no conflict of interest regarding the publication of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"132"}}